Company overview
The Cell and Gene Therapy Catapult (CGT Catapult) is an independent UK-based organization advancing cell and gene therapies through bioprocessing, formulation, characterization, and scalable manufacturing solutions. It supports development of viral vectors like rAAV and lentiviral vectors, as well as cell therapies from research to NHS patient access. CGT Catapult collaborates with industry, academia, and healthcare on automation, analytics, and commercialization challenges.
CGT Catapult is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving Europe & United Kingdom. Core focus areas include cell therapy, gene therapy, cgt manufacturing, viral vectors, atmp development.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://ct.catapult.org.uk/
- Categories
- CDMO & Manufacturing
- Markets served
- Europe & United Kingdom
- Keywords
- cell therapy, gene therapy, cgt manufacturing, viral vectors, atmp development
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What capabilities does CGT Catapult offer for gene therapy development?
- CGT Catapult provides bioprocessing, formulation, and characterization for viral vectors including rAAV, lentiviral, and non-viral platforms, focusing on scalability, cost-effectiveness, safety, and regulatory solutions.
- Does CGT Catapult support cell therapy manufacturing?
- Yes, it offers robust processes for autologous and allogeneic cell therapies, including automated robotic platforms and digital testbeds for scalable production.
- What geographies and regulatory support does CGT Catapult provide?
- Primarily UK-based with facilities in multiple locations, it supports ATMP development and commercialization to enable NHS patient access, including regulatory optimization for rAAV and other advanced therapies.
Related editorial coverage
- Navigating the 2026 Cell Therapy Regulatory Landscape
- AI Accelerates Novo Nordisk's Parkinson’s Cell Therapy
- European Biotechs Innovate in Cell and Gene Therapy Manufacturing
- Roche's Elevidys: A New Hope for DMD Gene Therapy Approval
- First GLP-1 Gene Therapy Clinical Trial Approved in Europe
- ISCT 2026: EU Manufacturing Innovations Day 1
Explore lab tools and QA/QC resources for R&D teams.
